Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,884 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05804578Recruiting
Blood test monitoring for metastatic breast cancer treatment
This trial studies using a blood test to monitor how treatment is working in people with metastatic breast cancer. It may help your care team track your cancer over time with a simpler test.
Kingston, OntarioAges 18 years+ - NCT05816655RecruitingPhase 2
Test two hormone treatment combinations for metastatic breast cancer
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
SeoulAges 19–80 - NCT05825456Recruiting
Study of surgery for broken bones from metastatic cancer
This trial looks at outcomes after surgery to stabilize a broken bone caused by cancer that has spread (metastatic cancer). It may help by improving how doctors plan and measure results after specific types of bone stabilization surgery.
Ankara, altindagAges Any age - NCT05832827RecruitingPhase 2
First treatment combo for thymic cancer using pembrolizumab plus drugs
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
Chūō, TokyoAges 18 years+ - NCT05838053Recruiting
Segmentectomy versus lobectomy for small lung cancer
This trial compares two types of lung surgery—removing a small lung segment versus removing an entire lung lobe—for small lung adenocarcinoma (≤ 2 cm). It may help you choose the safest approach that still controls the cancer.
Yangpu, Shanghai MunicipalityAges 20–79 - NCT05838066RecruitingPhase 3
KN026 plus HB1801 for HER2-positive advanced breast cancer
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
Beijing, chaoyangAges 18 years+ - NCT05854498RecruitingPhase 2
Study drug combination for metastatic colon cancer with prior treatments
This Phase 2 trial tests a chemotherapy combination (liposomal irinotecan), along with TAS-102 and bevacizumab, in people with metastatic colon cancer. It may help if your tumor has mismatch repair–proficient features and you’ve already tried standard colon cancer drugs.
Madison, WisconsinAges 18 years+ - NCT05868629Recruiting
Test of two targeted drugs for tumors with BRAF V600E
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
Torrance, CaliforniaAges 1–100 - NCT05885009Recruiting
Liquid biopsy test to guide treatment in metastatic prostate cancer
This study looks at using a simple blood test (liquid biopsy) to read tumor DNA and understand how it could affect treatment decisions. It is for adults with metastatic prostate cancer who are about to start, are receiving, or recently finished treatment.
BarcelonaAges 18 years+ - NCT05904964RecruitingPhase 3
Targeted drug for hormone-positive, HER2-low metastatic breast cancer
This Phase 3 trial tests disitamab vedotin (a targeted drug) in people with hormone receptor–positive, HER2-low metastatic breast cancer that can’t be cured with surgery or radiation. It aims to see whether the drug can control the cancer better than current standard care.
Guangzhou, GuangdongAges 18–70 - NCT05907681Recruiting
Study outcomes after precise targeted radiation for metastatic breast cancer
This study follows people with breast cancer that has spread to other parts of the body who receive a highly precise form of radiation (like IMRT, SBRT, or proton therapy). It aims to see how well this treatment strategy works and what outcomes patients experience.
SeoulAges 19–100 - NCT05911217RecruitingPhase 1
CT041 treatment after chemotherapy for resected pancreatic cancer
This Phase 1 study tests whether CT041 is safe and may help prevent pancreatic cancer from coming back after it’s been removed and you’ve completed standard chemotherapy. You may be eligible if your tumor is positive for CLDN18.2 and your recovery and blood tests meet key requirements.
Beijing, Beijing MunicipalityAges 18–79 - NCT05913388RecruitingPhase 2
Testing a new drug plus pembrolizumab versus pembrolizumab alone
This Phase 2 trial studies whether adding GB1211 to pembrolizumab works better than pembrolizumab with a placebo in people with metastatic melanoma or metastatic head and neck squamous cell cancer. It may help shrink tumors and improve outcomes, but it also carries risks from immune-based treatment.
Portland, OregonAges 18 years+ - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Fountain Valley, CaliforniaAges 18 years+ - NCT05947838Recruiting
Blood test helps choose chemotherapy before colorectal or appendix surgery
This study uses a blood test called ctDNA to help tailor (personalize) neoadjuvant chemotherapy for people with colorectal or appendix cancer before surgery. The goal is to see if using ctDNA can help doctors pick the most appropriate chemotherapy plan for you.
Houston, TexasAges 18 years+ - NCT05949541RecruitingPhase 2
Everolimus with first-line hormone therapy for specific breast cancer
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05954312RecruitingPhase 1
Study of an experimental drug for advanced solid tumors
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Jacksonville, FloridaAges 18 years+ - NCT05957250Recruiting
PET scan study to better image pancreatic and bile duct cancer
This study uses a special PET scan drug (Ga-FAPI-46) to create clearer pictures of pancreatic and bile duct cancers. It may help doctors decide on the best next steps—especially before surgery—by checking tumor size and looking for spread.
Amsterdam, North HollandAges 18 years+ - NCT05959291Recruiting
Stopping long-term anti-HER2 therapy in stable metastatic breast cancer
This study asks whether some people with HER2-positive metastatic breast cancer who have been stable for a long time can safely stop their ongoing (maintenance) anti-HER2 treatment. It also uses blood testing and close imaging follow-up to watch for early signs that treatment needs to restart.
Miami, FloridaAges 18 years+ - NCT05959356RecruitingPhase 2
First-line treatment for left-sided metastatic colon cancer with specific tumor markers
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
Foshan, GuangdongAges 18 years+ - NCT05961982Recruiting
EUS-guided heat treatment for pancreatic cysts
This study tests whether an endoscopy-based “radiofrequency ablation” (controlled heating) can manage certain pancreatic cysts that look high-risk. It’s designed for people who are not good candidates for surgery, aiming to shrink or control the cyst safely.
Columbus, OhioAges 18 years+ - NCT05962502RecruitingPhase 2
Cetuximab plus irinotecan for left-sided RAS/BRAF wild-type colon cancer
This Phase 2 trial tests whether adding cetuximab to irinotecan can control metastatic colorectal cancer that has returned or worsened after standard treatments. It targets people whose tumor is left-sided and shows “wild-type” RAS and BRAF genes on blood testing after prior therapy.
Guangzhou, GuangdongAges 18 years+ - NCT05964504Recruiting
Registry study for metastatic lobular breast cancer
This study collects health information from adults with invasive lobular breast cancer that has spread (metastatic) to help researchers understand factors linked to survival. Joining may help build better knowledge for future treatments and care planning.
San Diego, CaliforniaAges 18 years+ - NCT05977036Recruiting
Biomarker test to guide early treatment for HR+ HER2- breast cancer
This study uses a lab “biomarker” test to help doctors choose the best first treatment for people with HR+ (hormone-receptor positive), HER2-negative metastatic or unresectable breast cancer. The goal is to see if this biomarker-guided approach can improve which therapy you start with.
St Louis, MissouriAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,884 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.